menu
    • menu
    [{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Loperamide Hydrochloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Loperamide Hydrochloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Neratinib","moa":"||HER2\/4\/EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Loperamide Hydrochloride

    Menu

    Loperamide Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Granules India Limited

                            India
                            DCAT Week
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Loperamide Hydrochloride,Simethicone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Granules India Limited Received ANDA Approval for Loperamide HCl and Simethicone Tablets

                            Details : Generic of Loperamide Hydrochloride and Simethicone Tablets have been approved which is indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas.

                            Product Name : Imodium Multi-Symptom Relief-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2022

                            Lead Product(s) : Loperamide Hydrochloride,Simethicone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Specialised Therapeutics

                            Australia arrow
                            BioAsia
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neratinib,Capecitabine,Loperamide Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Breast Cancer Therapy Approved in Thailand to Reduce Recurrence Risk

                            Details : Nerlynx (neratinib) is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2 overexpressed/amplified breast cancer.

                            Product Name : Nerlynx

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Neratinib,Capecitabine,Loperamide Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zydus Lifesciences

                            India arrow
                            BioAsia
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loperamide Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Receives Final Approval from The USFDA for Loperamide Hydrochloride Capsules USP, 2 mg

                            Details : Loperamide hydrochloride binds to the opiate receptor in the gut wall and acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel.

                            Product Name : Imodium-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2023

                            Lead Product(s) : Loperamide Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Puma Biotechnology

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Puma Biotechnology

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neratinib,Loperamide Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Puma Biotechnology Publishes Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastati...

                            Details : Phase II SUMMIT ‘basket’ trial is an open-label, international multi-histology study to evaluate the safety and efficacy of neratinib, administered daily to patients, across a broad spectrum of cancer types in patients whose tumors harbor activating ...

                            Product Name : Nerlynx

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            July 27, 2020

                            Lead Product(s) : Neratinib,Loperamide Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth